This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 2022 May 1;140(5):484-485.

doi: 10.1001/jamaophthalmol.2022.0664.

Phase 4 Studies on Phosphodiesterase 5 Inhibitors

Brian L VanderBeek¹, Maureen G Maguire^{1

2}

Affiliations

PMID: 35389434
DOI: 10.1001/jamaophthalmol.2022.0664

Clinical Trial

Phase 4 Studies on Phosphodiesterase 5 Inhibitors

Brian L VanderBeek et al. JAMA Ophthalmol. 2022.

. 2022 May 1;140(5):484-485.

doi: 10.1001/jamaophthalmol.2022.0664.

Authors

Brian L VanderBeek¹, Maureen G Maguire^{1

2}

Affiliations

¹ Department of Ophthalmology, University of Pennsylvania, Philadelphia.
² JAEB Center for Health Research, Tampa, Florida.

PMID: 35389434
DOI: 10.1001/jamaophthalmol.2022.0664

No abstract available

PubMed Disclaimer

Comment on

Risk of Ocular Adverse Events Associated With Use of Phosphodiesterase 5 Inhibitors in Men in the US.
Etminan M, Sodhi M, Mikelberg FS, Maberley D. Etminan M, et al. JAMA Ophthalmol. 2022 May 1;140(5):480-484. doi: 10.1001/jamaophthalmol.2022.0663. JAMA Ophthalmol. 2022. PMID: 35389459 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems